MSMarius Schild

Marius Schild

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marius Schild has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Christina Sorbe

    Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

    2 shared publications
  • Kristina Lohmann

    Medical Affairs Germany, AbbVie GmbH & Co. KG, Wiesbaden, Germany

    2 shared publications
  • Thomas Bickert

    Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

    2 shared publications
  • Carl-Philipp Bürkle

    Skin and Laser Medicine, Dermatologist’s Practice Dr. med. Carl-Philipp Bürkle in Haslach

    1 shared publication
  • Johannes Hockmann

    Dermatologist’s Practice Dipl.-Psych. Dr. med. Johannes Hockmann in Oelde

    1 shared publication
  • Matthias Augustin

    Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE) Hamburg Deutschland

    1 shared publication

Latest Publications

  • Open Access

    Prevalence of Genital Psoriasis and Its Impact on Patients’ Sexual Life in Routine Care: Epidemiologic Survey in Germany

    by Toni Maria Janke, Christina Sorbe, Rachel Sommer, Thomas Bickert, Ulrich Mrowietz, Susana Gomis-Kleindienst, Marius Schild, Kristina Lohmann, Matthias Augustin

    Purpose: Psoriatic disease (PsO) involving the genital region (GenPsO) or areas of sexual interest (ASI; anal region, gluteal area, groin, lower back, and chest/breast) is associated with impaired quality of life (QoL), sexual burden, and avoidance of sexual life. This nested cohort study investigated the prevalence and effect of GenPsO and PsO at any ASI in routine German care. Methods: Adult patients enrolled in the PsoBest registry were surveyed by mail. Main endpoints were prevalences of GenPsO and PsO at any ASI in the past 12 and 24 months. The reasons for sexual impairment (RSI) questionnaire, the Genital Psoriasis Symptoms Scale (GPSS), the Genital Psoriasis Sexual Impact Scale, demographics, and disease characteristics were assessed. Results: Questionnaires were returned by 811/2010 (40.3%) patients; 795 (39.6%) complete sets were analyzed. Mean (SD) age at onset was 35.0 (14.0) years for GenPsO, and 34.1 (14.9) years for PsO at any ASI. Period prevalence was 21.6% (n=172) for GenPsO and 49.2% (n=391), for PsO at any ASI in the last 24 months, and 10.8% (n=86) and 26.7% (n=212), respectively, at day of survey. Systemic therapy was used by 84.9% (n=73) of patients with GenPsO and 83.0% (n=176) with PsO at any ASI. Mean (SD) GPSS sum score was 27.6 (18.6). In the past 30 days, 60.5% (n=52) of patients with GenPsO and 35.4% (n=75) with PsO at any ASI experienced sexual impairment. Among patients with GenPsO, 40.7% (n=35) reported always avoiding sexual activities during the past week. RSI included stress, lack of self-confidence, and PsO-related pain/movement restrictions. Conclusion: Given the high prevalence of GenPsO and its extensive effect on patient QoL and sexual well-being, it is essential that genital and ASI regions are examined at each routine clinical appointment and that appropriate treatment is offered to minimize negative consequences and cumulative life course impairment.


  • Open Access

    Reduction of impairment of sexual activity in patients with genital psoriasis treated with risankizumab: interim results of a real-world study

    by Nesrine Ben-Anaya, Tony Yip, Christina Sorbe, Thomas Bickert, Johannes Hockmann, Carl-Philipp Bürkle, Kristina Lohmann, Marius Schild, Matthias Augustin, Ralph von Kiedrowski

    Psoriasis involving the genital region (GenPsO) is associated with impaired quality of life (QoL), including sexual burden and avoidance of sexual intercourse. There is limited data on the effectiveness of risankizumab in GenPsO on patients' QoL and sexual impairment. GPS-Best, a nested cohort non-interventional study within the German Psoriasis registry PsoBest, aims to evaluate the effectiveness of risankizumab in GenPsO and its impact on QoL and sexual impairment. This interim analysis involves 52 patients who completed week 16 of the 52-week GPS-Best study. Patient questionnaires, including the Genital Psoriasis Symptoms Scale (GPSS) and Genital Psoriasis Sexual Impact Scale (GPSIS), were evaluated in patients with plaque psoriasis and a static physician's global assessment of genitalia ≥ 3 at baseline. The results demonstrated a significant reduction in the GPSS total score from a median [IQR] of 42.0 [36.0-57.0] at baseline to 3.0 [0-9.0] at week 16 (p < 0.001). In the GPSIS avoidance and impact subscale, more patients reported 'never' avoiding sexual activity at week 16 compared to baseline (46.8% vs. 10.5%) and 78.9% reported 'no or very low' impact compared to 18.5% at baseline, respectively. These findings indicate risankizumab significantly reduces patient-reported GenPsO symptoms over a 16-week period and increases sexual QoL.